Stem Cell Therapy for Parkinson's: New Data at ISSCR 2026
Researchers presented 12-month clinical data from the STEM-PD trial at the ISSCR 2026 meeting, showing the safety and feasibility of stem cell-derived dopaminergic cell transplantation for Parkinson's disease. This study marks a significant advancement in regenerative medicine by moving beyond proof-of-concept toward clinical application.
The International Society for Stem Cell Research (ISSCR) today announced the presentation of new clinical data from the STEM-PD Phase I/II clinical trial at the ISSCR 2026 Annual Meeting. The study reports 12-month outcomes evaluating a cryopreserved, off-the-shelf dopaminergic progenitor cell product derived from human pluripotent stem cells for the treatment of Parkinson's disease.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in